The Joe Rogan ExperienceJoe Rogan Experience #2251 - Rick Perry & W. Bryan Hubbard
CHAPTERS
- 0:00 – 1:46
Why Rick Perry & Bryan Hubbard are on: Kentucky’s ibogaine initiative and opioid settlement funds
Joe opens by asking how Rick Perry and W. Bryan Hubbard connected. Hubbard explains his public service role in Kentucky and how he designed the Kentucky Ibogaine Initiative using opioid settlement money. He credits Perry as a key advocate who helped legitimize and publicize the effort.
- 1:46 – 10:13
Rick Perry’s origin story: meeting Marcus Luttrell and seeing veterans fall through the cracks
Perry recounts a 2006 vacation encounter that led to a life-changing relationship with Navy SEAL Marcus Luttrell. Luttrell later arrived at the Texas governor’s mansion and ended up living with Perry’s family, exposing Perry to the realities of veterans’ trauma and inadequate government support. This experience set Perry on a long search for effective mental health solutions for veterans.
- 10:13 – 15:04
From skeptical to outspoken: Perry’s shift toward plant medicines (and distinction from drug legalization)
Perry explains how his stance evolved from strict anti-drug views to advocating medically supervised plant medicine. He cites early exposure to medical THC for epilepsy and draws a clear line between clinical use and broad drug legalization. He frames ibogaine advocacy as evidence-driven, safety-focused, and rooted in helping veterans.
- 15:04 – 17:35
Ads break, then ibogaine basics: not recreational, anti-addictive, and ‘rewiring’ claims
After sponsor messages, the conversation returns to ibogaine’s reputation and use-case. They emphasize it’s not a ‘party drug’ and argue it has no addiction potential while helping resolve addiction. Joe tees up the question of how ibogaine entered public awareness.
- 17:35 – 25:16
Ibogaine’s weird public debut and the Schedule I problem: Nixon-era policy and lasting consequences
They discuss how a Hunter S. Thompson rumor helped introduce ibogaine to public discourse, then pivot to why it’s still Schedule I. Perry argues Schedule I classification is politically rooted, not medically justified, and blocks research. The discussion centers on veterans’ suicides, international access, and the push to reschedule for trials.
- 25:16 – 34:15
Stanford/Nature Medicine study: VETS, the Ambio clinic, and reported neuroregenerative findings
Hubbard outlines the origins of VETS (Veterans Exploring Treatment Solutions) and how veterans traveled to Mexico for ibogaine treatment. He summarizes a Stanford-led study evaluating 30 veterans pre/post treatment, including MRI-based brain-age comparisons and symptom changes. They also introduce broader neurodegenerative-disease anecdotes that fuel calls for U.S. trials.
- 34:15 – 47:03
‘Too good to be true’ vs lived experience: why Perry is willing to risk his reputation
Joe expresses skepticism that outcomes can be so consistently dramatic; Perry and Hubbard acknowledge the concern but point to repeated testimonials. Perry explains he has studied and observed clinics and is motivated by the belief that veterans’ lives outweigh political risk. They cite more public veteran advocates and the moral argument for access.
- 47:03 – 52:03
How ibogaine may end opioid dependence: Lotsof history, dopamine/serotonin restoration theory, and meth use-case
Hubbard gives a historical and mechanistic narrative starting with Howard Lotsof’s 1962 discovery. He frames addiction as neurochemical injury and claims ibogaine restores dopamine/serotonin production rapidly compared with the long abstinence timeline. He also notes ibogaine’s reported effectiveness for meth dependence, raising stakes in the fentanyl+meth era.
- 52:03 – 55:51
Safety realities: cardiac risk, QT prolongation, and why medical supervision matters
Hubbard emphasizes ibogaine is powerful and potentially dangerous if administered incorrectly. He explains QT prolongation and torsades risk, outlines best-practice mitigation (including magnesium), and strongly warns against self-administration or unvetted clinics. He names information resources and clinics he considers high standard.
- 55:51 – 1:06:28
Hubbard’s personal and professional arc: Appalachia roots, law disillusionment, and seeing opioid devastation up close
Hubbard shares his upbringing in coal country and generational trauma from addiction and untreated mental illness, alongside formative spiritual guidance from his grandfathers. He describes entering law with idealism, then practicing workers’ compensation during the opioid boom and witnessing how pain, despair, and overprescribing intertwined. This sets up his transition into Kentucky government roles focused on system performance and accountability.
- 1:06:28 – 1:18:05
Kentucky government deep dive: disability growth, Medicaid prescribing metrics, corruption, and opioid-abatement opportunity
Hubbard recounts running Kentucky’s Social Security Disability system and child support enforcement, describing incentives that expand bureaucracy and dysfunction. He shares metrics on enrollment growth and prescribing increases, and details reform efforts that created political backlash. He then explains taking on opioid settlement governance and insisting on transparency to avoid ‘buzzards’ capturing the funds.
- 1:18:05 – 1:34:41
The Kentucky Ibogaine Initiative rises—and gets derailed: confidential NYC network, public hearings, FDA testimony, then political reversal
Hubbard details how he learned about ibogaine through psychedelic research interest, built a confidential network, and pitched ibogaine as Kentucky’s breakthrough therapeutic project. He describes three major public hearings (science, testimonials, FDA feasibility), highlighting FDA experts who said risk mitigation—not risk existence—determines trial approval. Momentum collapsed after elections and leadership changes, leading to his forced resignation.
- 1:34:41 – 1:43:43
Texas plan: legislation, funding, clinical trial roadmap, and public ROI safeguards
Perry and Hubbard pivot to Texas as the new vehicle for scaling ibogaine research, citing earlier Texas psilocybin trial legislation as precedent. They outline a proposed appropriation, solicitation of drug developers, FDA trial design, and safeguards ensuring Texans retain an interest in resulting IP. The focus is building a medically rigorous in-state infrastructure leveraging Texas’ medical institutions.
- 1:43:43 – 2:07:09
Broader coalition and closing themes: national state-by-state momentum, spirituality, and a call to action
They describe expanding momentum beyond Texas with other states organizing parallel efforts, and discuss how ibogaine experiences are framed as spiritually transformative. Hubbard shares personal testimony about ibogaine (and later 5-MeO-DMT) affecting his and his wife’s mental health trajectory, then broadens to a critique of dehumanizing systems. The episode ends with a call for civic engagement, public education, and prayers for success.
